Literature DB >> 27717891

The rs767649 polymorphism in the promoter of miR-155 contributes to the decreased risk for cervical cancer in a Chinese population.

Shizhi Wang1, Xiaoli Cao2, Bo Ding3, Jinfeng Chen4, Mengjing Cui5, Yuling Xu5, Xiaoyun Lu6, Zhengdong Zhang7, Aiqin He4, Hua Jin8.   

Abstract

Genetic variants in miRNAs have attracted more and more attention these years because they are capable of altering miRNA function and/or expression, consequently affecting downstream biological pathways and disease risk. The rs767649 polymorphism, locating in the promoter of miR-155, was recently reported to be able to alter transcriptional activity of miR-155 and relate to lung cancer risk. In this study, we aimed to assess the relationship between rs767649 and cervical cancer (CC) risk. We investigated the association of rs767649 with CC risk in a two-stage case-control study with 1157 cases and 1280 controls. Genotyping was determined with TaqMan allelic discrimination method. The results showed that the rs767649 TT genotype was associated with a significantly reduced risk of CC in both test (549 cases and 603 controls), validation (608 cases and 677 controls) and combined sets [adjusted odds ratio (OR)=0.67, 95% confidence interval (CI)=0.51-0.87 for the combined set] compared with the AA/AT genotypes. Moreover, the association was more prominent among patients of age>49years and postmenopausal status (OR=0.56, 95% CI=0.38-0.83, and 0.60, 0.40-0.89, respectively) and patients with clinical stage I and II CC (OR=0.67, 95% CI=0.50-0.91, and 0.60, 0.40-0.92, respectively). Further analyses showed that miR-155 was overexpressed in the CC tissues as compared with normal tissues, suggesting an oncogenic role in CC. Luciferase assay indicated that the transition of A to T allele might lead to miR-155 downregulation at the transcriptional level. In conclusion, rs767649 might be a causal variant for CC susceptibility.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cervical cancer; Susceptibility; miR-155; rs767649

Mesh:

Substances:

Year:  2016        PMID: 27717891     DOI: 10.1016/j.gene.2016.10.002

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  6 in total

1.  Functional polymorphisms in the promoter region of miR-17-92 cluster are associated with a decreased risk of colorectal cancer.

Authors:  Ruifen Sun; Yundan Liang; Fang Yuan; Xinwen Nie; Hong Sun; Yanyun Wang; Tao Yu; Linbo Gao; Lin Zhang
Journal:  Oncotarget       Date:  2017-07-31

2.  Polymorphisms in miRNA genes play roles in the initiation and development of cervical cancer.

Authors:  Zhiling Yan; Ziyun Zhou; Chuanyin Li; Xielang Yang; Longyu Yang; Shuying Dai; Jiehan Zhao; Huijing Ni; Li Shi; Yufeng Yao
Journal:  J Cancer       Date:  2019-08-20       Impact factor: 4.207

3.  The miR-146a SNP Rs2910164 and miR-155 SNP rs767649 Are Risk Factors for Non-Small Cell Lung Cancer in the Iranian Population.

Authors:  Neda K Dezfuli; Ian M Adcock; Shamila D Alipoor; Sharareh Seyfi; Babak Salimi; Maryam Mafi Golchin; Neda Dalil Roofchayee; Mohammad Varhram; Esmaeil Mortaz
Journal:  Can Respir J       Date:  2020-11-20       Impact factor: 2.409

4.  Association between genetic variants of microRNA-21 and microRNA-155 and systemic lupus erythematosus: A case-control study from a Chinese population.

Authors:  Rong Wang; Anji Wei; Yingjie Zhang; Guidan Xu; Xuejuan Nong; Chunhong Liu; Yonglong Zeng; Huatuo Huang; Xiaoxia Pang; Wujun Wei; Chunfang Wang; Huayi Huang
Journal:  J Clin Lab Anal       Date:  2022-06-16       Impact factor: 3.124

5.  The association between polymorphisms in microRNA genes and cervical cancer in a Chinese Han population.

Authors:  Li Chuanyin; Wang Xiaona; Yan Zhiling; Zhang Yu; Liu Shuyuan; Yang Jie; Hong Chao; Shi Li; Yang Hongying; Yao Yufeng
Journal:  Oncotarget       Date:  2017-09-23

6.  Gene polymorphism and plasma levels of miR-155 in diabetic retinopathy.

Authors:  E R Polina; F M Oliveira; R C Sbruzzi; D Crispim; L H Canani; K G Santos
Journal:  Endocr Connect       Date:  2019-12       Impact factor: 3.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.